Autopsy report · NCT01101906
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
Cause of deathFunding or business
“Company decided not to pursue the development of this drug in this patient population at this time”
Life of this trial
- Registered 9 months before it started.
- Ran for about 1 year before it stopped.
- 23 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Astellas Pharma Inc
- Sponsor type
- Industry
- Conditions
- Advanced Hepatocellular Carcinoma (HCC)
- Interventions
- OSI-906; Placebo
- Participants
- 23
- Sites
- 41
- Countries
- Belgium, France, Germany, Hong Kong, Italy, Singapore, South Korea, Spain, Taiwan, United States
Trials that died the same way
- Panobinostat/Velcade in Multiple Myeloma
“This study was terminated because the drug company stopped making the study drug” - Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
“due to business decision regarding the study drug.” - MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
“Drug provider decided not to move forward with the study.” - Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
“This study was withdrawn due to a strategic business decision; no patients were enrolled.” - Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Endodontics
“Manufacturer discontinued drug before any participants could be enrolled.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.